A β-Clearing Drug Fails to Slow Alzheimer Disease

Verubecestat, an oral β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) inhibitor, did not reduce cognitive or functional decline in patients with mild to moderate Alzheimer disease in a phase 3trial published in theNew England Journal of Medicine. Verubecestat had previously been shown to reduce amyloid-beta (A β) levels in the cerebrospinal fluid of healthy people and patients with Alzheimer disease.
Source: JAMA - Category: General Medicine Source Type: research